Cisplatin/Paclitaxel Co-formulation
Cancer
PreclinicalActive
Key Facts
About Adeira Pharma
Adeira Pharma is a private, preclinical biotech leveraging a versatile targeted nanoparticle platform to overcome historical drug formulation challenges. Its core technology enables the encapsulation or surface attachment of diverse therapeutic payloads, aiming to enhance pharmacokinetics, reduce toxicity, and improve targeted delivery. The company is currently seeking development partners for its lead reformulation candidates, primarily in oncology, and operates a partnership-focused business model without disclosed revenue.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |